Your browser doesn't support javascript.
loading
Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome.
Kennedy, Alyssa L; Myers, Kasiani C; Bowman, James; Gibson, Christopher J; Camarda, Nicholas D; Furutani, Elissa; Muscato, Gwen M; Klein, Robert H; Ballotti, Kaitlyn; Liu, Shanshan; Harris, Chad E; Galvin, Ashley; Malsch, Maggie; Dale, David; Gansner, John M; Nakano, Taizo A; Bertuch, Alison; Vlachos, Adrianna; Lipton, Jeffrey M; Castillo, Paul; Connelly, James; Churpek, Jane; Edwards, John R; Hijiya, Nobuko; Ho, Richard H; Hofmann, Inga; Huang, James N; Keel, Siobán; Lamble, Adam; Lau, Bonnie W; Norkin, Maxim; Stieglitz, Elliot; Stock, Wendy; Walkovich, Kelly; Boettcher, Steffen; Brendel, Christian; Fleming, Mark D; Davies, Stella M; Weller, Edie A; Bahl, Christopher; Carter, Scott L; Shimamura, Akiko; Lindsley, R Coleman.
Afiliação
  • Kennedy AL; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
  • Myers KC; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Bowman J; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
  • Gibson CJ; Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
  • Camarda ND; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
  • Furutani E; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Muscato GM; Institute for Protein Innovation, Boston, MA, USA.
  • Klein RH; Department of Medical Oncology, Division of Hematological Malignancies Dana-Farber Cancer Institute, Boston, MA, USA.
  • Ballotti K; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Liu S; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
  • Harris CE; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Galvin A; Boston Children's Hospital, Boston, MA, USA.
  • Malsch M; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Dale D; Broad Institute, Boston, MA, USA.
  • Gansner JM; Boston Children's Hospital, Boston, MA, USA.
  • Nakano TA; Biostatistics and Research Design Center, Institutional Centers for Clinical and Translational Research, Boston Children's Hospital, Boston, MA, USA.
  • Bertuch A; Boston Children's Hospital, Boston, MA, USA.
  • Vlachos A; Boston Children's Hospital, Boston, MA, USA.
  • Lipton JM; Boston Children's Hospital, Boston, MA, USA.
  • Castillo P; Department of Internal Medicine, University of Washington, Seattle, WA, USA.
  • Connelly J; Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
  • Churpek J; Center for Cancer and Blood Disorders, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, CO, USA.
  • Edwards JR; Department of Pediatrics/Hematology-Oncology, Baylor College of Medicine, Houston, TX, USA.
  • Hijiya N; Division of Hematology/Oncology and Cellular Therapy, Cohen Children's Medical Center of New York, New Hyde Park, NY, USA.
  • Ho RH; Zucker School of Medicine at Hofstra/Northwell School of Medicine, Hempstead, NY, USA.
  • Hofmann I; Division of Hematology/Oncology and Cellular Therapy, Cohen Children's Medical Center of New York, New Hyde Park, NY, USA.
  • Huang JN; Zucker School of Medicine at Hofstra/Northwell School of Medicine, Hempstead, NY, USA.
  • Keel S; Shands Children's Hospital, Department of Pediatrics, Division of Pediatric Hematology Oncology, University of Florida, Gainesville, FL, USA.
  • Lamble A; Department of Pediatrics, Division of Pediatric Hematology Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Lau BW; Department of Medicine, Section of Hematology, Oncology, and Palliative Care, The University of Wisconsin-Madison, Madison, WI, USA.
  • Norkin M; Indiana Blood and Marrow Transplantation, Indianapolis, IN, USA.
  • Stieglitz E; Department of Pediatrics, Columbia University Medical Center, New York, NY, USA.
  • Stock W; Department of Pediatrics, Division of Pediatric Hematology Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Walkovich K; Department of Pediatrics, Division of Pediatric Hematology/Oncology and BMT, University of Wisconsin, Madison, WI, USA.
  • Boettcher S; Department of Pediatrics, UCSF Benioff Children's Hospital, San Francisco, CA, USA.
  • Brendel C; Division of Pediatric Allergy, Immunology, and Blood & Marrow Transplantation, UCSF Benioff Children's Hospital, San Francisco, CA, USA.
  • Fleming MD; Division of Hematology, Department of Medicine, University of Washington, Seattle, WA, USA.
  • Davies SM; Division of Hematology-Oncology, Seattle Children's Hospital, Seattle, WA, USA.
  • Weller EA; Dartmouth-Hitchcock Medical Center, Pediatric Hematology Oncology, Geisel School of Medicine, Lebanon, NH, USA.
  • Bahl C; Department of Medicine, University of Florida, Gainesville, FL, USA.
  • Carter SL; Division of Cancer Medicine, Baptist MD Anderson Cancer Center, Jacksonville, FL, USA.
  • Shimamura A; Department of Pediatrics, UCSF Benioff Children's Hospital, San Francisco, CA, USA.
  • Lindsley RC; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
Nat Commun ; 12(1): 1334, 2021 02 26.
Article em En | MEDLINE | ID: mdl-33637765
ABSTRACT
To understand the mechanisms that mediate germline genetic leukemia predisposition, we studied the inherited ribosomopathy Shwachman-Diamond syndrome (SDS), a bone marrow failure disorder with high risk of myeloid malignancies at an early age. To define the mechanistic basis of clonal hematopoiesis in SDS, we investigate somatic mutations acquired by patients with SDS followed longitudinally. Here we report that multiple independent somatic hematopoietic clones arise early in life, most commonly harboring heterozygous mutations in EIF6 or TP53. We show that germline SBDS deficiency establishes a fitness constraint that drives selection of somatic clones via two distinct mechanisms with different clinical consequences. EIF6 inactivation mediates a compensatory pathway with limited leukemic potential by ameliorating the underlying SDS ribosome defect and enhancing clone fitness. TP53 mutations define a maladaptive pathway with enhanced leukemic potential by inactivating tumor suppressor checkpoints without correcting the ribosome defect. Subsequent development of leukemia was associated with acquisition of biallelic TP53 alterations. These results mechanistically link leukemia predisposition to germline genetic constraints on cellular fitness, and provide a rational framework for clinical surveillance strategies.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndrome de Shwachman-Diamond / Hematopoiese Clonal Limite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male / Middle aged Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndrome de Shwachman-Diamond / Hematopoiese Clonal Limite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male / Middle aged Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos